Tech Company Financing Transactions

RareCyte Funding Round

5AM Ventures, private investors and Telegraph Hill Partners invested in a $30 million funding round for RareCyte. The round was announced on 8/11/2017.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

2601 4th Ave.
Seattle, WA 98121
USA

Phone

(206) 455-9092

Website

www.rarecyte.com

Email Address

[email protected]

Overview

RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood. Our team of biologists and engineers is dedicated to building innovative technologies to better understand human health and disease.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Joe Victor

        

Chief Medical Officer

Eric Kaldjian

        

VP - Bus. Development

Leighton Howells

        

VP - Engineering

Steve Reese

        

VP - Finance

James Cooper

        

VP - Operations

Tony Dedeo

        

VP - Product Management

Josh Nordberg

        

VP - R & D

Tad George

        

Browse more venture capital transactions:

Prev: 8/11/2017: Brayola venture capital transaction
Next: 8/11/2017: Essential venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary